Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

@article{Canessa2017ShiftFI,
  title={Shift from intravenous or 16\% subcutaneous replacement therapy to 20\% subcutaneous immunoglobulin in patients with primary antibody deficiencies},
  author={Clementina Canessa and Jessica Iacopelli and Antonio Pecoraro and Giuseppe Spadaro and Andrea Matucci and Cinzia Milito and Alessandra Vultaggio and Carlo Agostini and Francesco Cinetto and Maria Giovanna Danieli and Simona Gambini and Carolina Marasco and Antonino Trizzino and Angelo Vacca and Domenico De Mattia and Baldassarre Martire and Alessandro Plebani and Mario Di Gioacchino and Alessia Gatta and Andrea Finocchi and Francesco Licciardi and S. Martino and Marco de Carli and Viviana Moschese and Chiara Azzari},
  journal={International Journal of Immunopathology and Pharmacology},
  year={2017},
  volume={30},
  pages={73 - 82}
}
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®) has been developed and has replaced Vivaglobin® (SCIG 16%). An observational prospective multi-centric open-label study, with retrospective comparison was conducted in 15 Italian centers, in order to investigate whether and to what extent switching to Hizentra® would… 
View on SAGE
journals.sagepub.com
21 Citations
Background Citations
1
Methods Citations
1

Figures and Tables from this paper

21 Citations

Citation Type

Citation Type

Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
TLDR
In a real-life setting, in the Manitoba adult PIDD population, SCIG push is an effective method of preventing severe infections, with most patients preferring to continue this therapy once initiated.
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients
TLDR
It is suggested that 20% SCIg treatment represents a viable and safe treatment for PM/DM patients and a valid therapeutic alternative to IVIg, with important advantages for patients’ quality of life.
Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
TLDR
Patients with primary immunodeficiency diseases reported high levels of treatment satisfaction, convenience, and preference for Ig20Gly, with consistent results across studies and use of multiple patient-reported outcome measures.
Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies
TLDR
Findings support the concept that the cumulative monthly dose ofSCIG and the dose of SCIG per kilogram of body weight affect IgG trough levels in PAD patients, irrespective of BMI.
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study.
TLDR
Biweekly Hizentra is a noninferior option with respect to previous IVIG/SCIG-based treatment in patients with PID, and there were no differences in the number of infections.
Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
TLDR
Real-life data suggest that long-term repeated self-administration of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulins results in a reduced rate of infectious events if compared to the pre-treatment rate.
Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
TLDR
In pediatric PID patients, weekly and biweekly Hizentra ® administrations appeared equally effective treatment options.
Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases
TLDR
The use of high-dose SCIg is generally feasible and safe in patients with inflammatory myopathies andRenal function was stable over the study period in all patients and the treatment was not withdrawn during the first year in any patient for safety issues.
Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach
...
...

References

SHOWING 1-10 OF 21 REFERENCES
Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach
TLDR
Hizentra is an advance in the field of immunoglobulin replacement therapy, which might offer benefits for home therapy patients and may allow shorter infusion times due to smaller infusion volumes, with potential improvement in the convenience of SCIG therapy.
Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases
TLDR
It is concluded that subcutaneous administration of 16% SCIg is a safe and effective alternative to IVIg for replacement therapy of PIDD.
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin…
Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National Study
TLDR
In conclusion, the SCIG administration route was safe, and high IgG levels were easily maintained resulting in a very good protection against infections.
Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency
TLDR
Although transition to a different SCIG product initially increased AEs, Hizentra is well tolerated and can be infused more rapidly and with fewer sites compared to Vivaglobin, which has similar pharmacokinetics and efficacy.
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route.
  • A N N Gardulf
  • Medicine
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2007
TLDR
This review demonstrates that subcutaneous IgG therapy is safe, with very few adverse effects, and facilitates home therapy, as the infusion technique is easy for children, adults and elderly people to learn and there is no need for venous access.
Subcutaneous immunoglobulin replacement in primary immunodeficiencies.
Immunoglobulin Treatment for Primary Antibody Deficiencies
TLDR
This review demonstrates that subcutaneous IgG therapy is safe, with very few adverse effects, and facilitates home therapy, as the infusion technique is easy for children, adults and elderly people to learn and there is no need for venous access.
...
...